Navigation Links
CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
Date:12/19/2007

ment programs will not proceed as planned for technical, scientific, regulatory or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Glenn Schulman, PharmD

Director of Investor Relations

gschulman@curagen.com

(888) 436-6642

CRGN-P


'/>"/>
SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
2. CuraGen Appoints Clinical Oncologist as VP of Medical Development
3. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...s., Sept. 5 /- Men living in Western,...h an enlarged prostate,now have the option of out-...biolitec, Inc. is pleased to announce that a netwo...s breakthrough LIFE(TM) (Laser Induced,Flow Enhanc...asia (BPH),that quickly and gently eliminates swol...
(Date:9/5/2008)...Regulatory Strategy for Belinostat in PTCL, COPEN... -- TopoTarget,A/S (OMX: TOPO) announced that a po...l Protocol Assessment (SPA) for a phase III trial ...a). This pivotal trial is to enrol,approximately 1...st Track,designation was granted for the developme...
(Date:9/5/2008).... 5 /- BioSpecifics,Technol...aceutical company,developing first in class collag...signed an agreement to significantly improve the d...s for Peyronie,s disease by buying down its,future..., BioSpecifics has modified its previously announ...
(Date:9/4/2008).... 4 /- Hologic, Inc.,(Nasda...Financial Officer,will be presenting at the Morga...eing held September 9, 2008, at the Grand Hyatt Ho...ted to listen to a live audio webcast of,Hologic,s...08, at 1:35 PM.,Eastern Time on the investor sect...
Breaking Biology Technology:Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon 2Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 2Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 3Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 4Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL 5BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
...d, Wis. - Determining how technology can help dri... an honest assessment of what doesn,t make sense...cal research institution in its backyard, it simpl...t spot," even if free land and tax incentives are ...g Wisconsin, scrambling to find the right niche wi...
... Wis. - For future generations of Native American...ld lead through some high-tech corridors. , ,An ef... adopting a more aggressive investment strategy, o...ology industry and the state economy. , ,After inv... and an IT firmthe Forest County Potawatomi Commu...
...is. - Following the announcement of increased qua... of rich-media technology, once again projected ca... with full year profitability projected for 2007. ...Minor released upbeat results for Sonic Foundry,s ...ilizing the company,s synchronized web presentatio...
..., Wis. - With its Investor Day program scheduled ...ews to spread. , ,The Brookfield-based global pro...es has reported stronger earnings for the second q... percentage increase in total revenues during the ... for the quarter increased 10 percent to $1.09 bil...
Other Biology Technology:Technology in the Northwoods 2Technology in the Northwoods 3Potawatomis to ramp up their investing 2Potawatomis to ramp up their investing 3Sonic closer to turning profit corner 2Sonic closer to turning profit corner 3Sonic closer to turning profit corner 4Fiserv reports stronger earnings and revenues 2Fiserv reports stronger earnings and revenues 3
(Date:9/4/2008)...ing researchers at the HudsonAlpha Institute and S...a number of other organizations, today publishes a...e brain cancer glioblastoma. These results are the...h network, a collaborative effort funded by the Na...ome Research Institute of the National Institutes ...
(Date:9/4/2008)...logy company have joined forces to develop a world... to predict premature birth with greater accuracy....Newcastle and Symbion Pathology are combining,exp...ogy to develop a computer program to predict,wome...-term births occur in Australia each year. Prematu...
(Date:9/4/2008)...ext great leap in medicine. In the future, new tis...heart, or new cells take the place of damaged cell...embryonic sources, which opens difficult ethical a...been looking to adult human stem cells, culled fro...ing cultivated from various tissues in the body &#...
(Date:9/4/2008)...of many serious diseases remain a mystery? In con...ity of California, San Diego School of Medicine ha...ivisible unit of life, the cell, which may provide...disciplines, Jamey Marth, Ph.D., UC San Diego Prof...tigator with the Howard Hughes Medical Institute, ...
Breaking Biology News(10 mins):Collaboration between researchers yields more comprehensive portrait of brain cancer 2World-first to predict premature births 2Tel Aviv University researchers create new stem cell screening tool 2Do 68 molecules hold the key to understanding disease? 2Money Matters 25459 3/ 1Stater Bros Raises 24200 000 for the Leukemia 26 Lymphoma Society 25457 1Stater Bros Raises 24200 000 for the Leukemia 26 Lymphoma Society 25457 2Older Adults Reluctant to Question Surgical Treatment 25455 1Older Adults Reluctant to Question Surgical Treatment 25455 2Light receptors in eye play key role in setting biological clock study shows 4480 1Light receptors in eye play key role in setting biological clock study shows 4480 2
...Consejo Superior de Investigaciones Científicas (C...of proteins in plant cells, a discovery that will ...ies. Amongst other applications, these can be used...ed, will be able to immunise against diseases. Mor... of protein-manufacturing plants of great interest...
...ice of killing wild badgers to prevent tuberculosi... newstudy led by Rosie Woodroffe, an ecologist at ...f Britain,s Independent Scientific Group on Cattle...otectionists have battled for 30 years over the me...is, a disease which can occasionally be transmitte...
...t on embryonic stem cells also has been found on t...ry that may help researchers isolate and purify ad...healing, tendon repair and cartilage regeneration,...ort. , The molecule, called SSEA-4, was found on t...at give rise to fat, cartilage and bone. These so-...
...f scientists has published the first two genome se...s called Phytophthora--a name that literally means...ngus-like Phytophthora (pronounced "fy-TOFF-thor-u...st the agriculture, forestry and nursery industrie...n though Phytophthora are similar to fungi, most f...
Other Biology News:Vaccine-producing 'plant-factories' 2British cattle give TB to badgers, finds UC Davis expert 2Molecular 'marker' on stem cells aids research, perhaps therapies 2Genome info from 'plant destroyers' could save trees, beans and chocolate 2
BD FACSAria Cell Sorting System from BD Biosciences - Immunocytometry Systems
...tial for hunting and analyzing the rare transcript...quencing projects, microarrays, functional screeni...ed for normalization of cDNA enriched with full-le...g. While most normalization methods are not well s...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)
Biology Products: